Results 261 to 270 of about 340,102 (305)

Immuno-analytical characteristics of PSA and derived biomarkers (total PSA, free PSA, p2PSA)

Annales de Biologie Clinique, 2023
Prostate-specific antigen (PSA) is the recommended tumor marker for individual screening and follow-up of prostate cancer. This paper reviews main structural and physiological data about prostate specific antigen isoforms: total PSA, free PSA, [-2]proPSA (also named p2PSA).
Cédric, Desbène, Mathieu, Boissan, Sylvain, Loric, Pierre-Jean, Lamy, Laurence, Piéroni   +4 more
openaire   +2 more sources

The PSA conundrum

Radiotherapy and Oncology, 2004
Several articles have appeared recently in Radiotherapy & Oncology [4,8,9,11,15,16] that warranted a critical reappraisal of the use of Prostate Specific Antigen (PSA) levels for determining in routine clinical practice whether or not the treatment of prostate cancer by radiotherapy was successful.
openaire   +2 more sources

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

Urology, 1999
To enhance the specificity of prostate cancer (PCa) detection and reduce unnecessary biopsies in men with prostate-specific antigen (PSA) levels of 2.5 to 4.0 ng/mL, we prospectively evaluated various PSA-based diagnostic parameters.This study included 273 consecutive men with serum PSA of 2.5 to 4.0 ng/mL referred for early PCa detection or lower ...
B, Djavan, A, Zlotta, C, Kratzik, M, Remzi, C, Seitz, C C, Schulman, M, Marberger   +6 more
openaire   +2 more sources

Time to Nadir PSA

American Journal of Clinical Oncology, 2015
The objective of the study was to investigate prostate-specific antigen (PSA) nadir (nPSA) and time to nPSA (TnPSA) as prognostic variables for outcomes after definitive high-dose (>75 Gy) external beam radiation therapy (RT) without androgen deprivation therapy while correcting for immortal-time bias.nPSA and TnPSA were available for 410 patients ...
Skyler B, Johnson, William C, Jackson, Jure, Murgic, Felix Y, Feng, Daniel A, Hamstra   +4 more
openaire   +2 more sources

Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?

Urology, 2000
To ascertain when the serum determination of the free prostate-specific antigen (PSA)/total PSA (fPSA/tPSA) ratio is clinically useful, and whether the identification of PSA or prostate-specific membrane antigen (PSM) mRNA in circulating cells has diagnostic advantages over the determination of their protein product.fPSA, tPSA, and the fPSA/tPSA ratio ...
BASSO, DANIELA, FOGAR, PAOLA, M. G. Piva, F. Navaglia, S. Mazza, T. Prayer Galetti, E. Castellucci, PAGANO, FRANCESCO, PLEBANI, MARIO   +8 more
openaire   +2 more sources

Standardization of PSA determinations

Scandinavian Journal of Clinical and Laboratory Investigation, 1995
Standardization of determinations for prostate specific antigen (PSA) has become an important issue due to the widespread use of these determinations for prostate cancer screening. Standardization of this assay is complicated due to the occurrence of two major forms of PSA in serum, the free antigen and a complex between PSA and alpha 1 ...
U H, Stenman, J, Leinonen, W M, Zhang
openaire   +2 more sources

Efforts for Improving the Efficiency of PSA: PSA Density, PSA Velocity, Age-specific PSA, and Free and Complexed PSA

Türk Üroloji Seminerleri/Turkish Urology Seminars, 2013
Omer Kutlu, Ismail Turker Koksal
openaire   +1 more source

Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases

Biosensors and Bioelectronics, 2021
Ana Díaz-Fernández, Rebeca Miranda-Castro, Noémi De-Los-Santos-Álvarez   +2 more
exaly  

To PSA or not to PSA...

The Journal of Men's Health & Gender, 2005
openaire   +1 more source

PSA assays

The Lancet Oncology, 2000
openaire   +2 more sources